This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The annual risk reduction for first coronary event was 27% for the first five years. Thereafter, the annual risk was assumed to be equivalent to the risk if there had been no treatment. The proportion of fatal coronary events among all coronary events for the age group 35 to 64 years old was 7.7% for men and 2.2% for women. The corresponding value for the group aged 65 years or older was 14.4% and 5.7%, respectively.
Clinical conclusions
Not reported.
Modelling
A Markov model was used to estimate cost and benefits. The model dealt with the uncertainty in the occurrence of a cardiovascular event or death from a non-coronary cause. The probabilities for the model were calculated from hazard functions estimated from Poisson models for the placebo group.
Measure of benefits used in the economic analysis
The benefits were expressed in terms of life-years gained. A Markov model was used to deal with the uncertainty in health status after initiation of treatment and, by doing so, to translate clinical outcomes (i.e. annual risk reduction with intervention for first coronary event) to an estimate of effectiveness in terms of life-years gained. Benefits from intervention were assumed to last for a period of 5 years.
Direct costs
Costs were discounted. Cost items were reported separately and were analysed on a cost per year basis (i.e. cost of the first, second etc., year after a coronary event). The costs measured were operating costs (drug) and cost of complications (associated with coronary event occurrence). The boundary adopted was that of the health care system. The resource quantities were based on actual data published in 1994. The broad (unit) costs estimates were based on the official retail price of the drug in Sweden from published sources of 1994 and 1995, and for hospitalisation costs, from actual costs of hospitalisation for patients in various diagnosis-related groups at 4 hospitals in Sweden with patientbased cost accounting systems. The prices used were those prevailing in 1995. Costs associated with physician visits and laboratory tests were excluded as they were assumed to be common. Costs avoided were considered for a period of 5 years only.
Indirect Costs
Costs were discounted and were analysed on a cost per year basis. The costs measured were those associated with productivity losses. The boundary used was the 'patient'. The resource quantities were based on actual quantities published in 1994 (estimates based on work status assessed every 6 months). The unit cost used was the average annual cost for the labour of a full-time Swedish worker in 1995. Costs avoided were considered for a period of 5 years only.
Currency
US dollars ($). The original figures were collected in Swedish Kroner (SEK) and the conversion rate used was $1= SEK7.30 (1995 rate).
